Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130305100959im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection. RBT represents an alternative to RMP for HIV infected patients as its half-life is longer and the enzymatic induction effect appears to be less important on the associated antiretroviral therapy (ART) drugs.
This phase II trial is to determine precisely the pharmacokinetics parameters of RBT in combination with different ART regimens in Vietnamese HIV infected patients with pulmonary tuberculosis, in order to define optimal doses that will be further tested in a larger phase III trial comparing safety, tolerability and efficacy of RBT and RMP regimens.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Tuberculosis |
Drug: rifabutin in combination with efavirenz Drug: rifabutin in combination with nevirapine Drug: rifabutin in combination with lopinavir/ritonavir |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Bio-availability Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial |
- Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with efavirenz, nevirapine or lopinavir/ritonavir) [ Time Frame: 2, 6 and 10 weeks after randomisation ] [ Designated as safety issue: No ]
- Area under the curve (AUC) of efavirenz, nevirapine and lopinavir/ritonavir in combination with two doses of rifabutine [ Time Frame: 6 and 10 weeks after randomisation ] [ Designated as safety issue: No ]
- Safety : proportion of patients with grade 3 and grade 4 adverse events [ Time Frame: through out the trial ] [ Designated as safety issue: Yes ]
Estimated Enrollment: | 48 |
Study Start Date: | February 2009 |
Study Completion Date: | October 2010 |
Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
RBT associated with EFV based ART
|
Drug: rifabutin in combination with efavirenz
Ia. arm 1a: D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks); Ib. arm 1b: D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks); |
Experimental: 2
RBT associated with NVP based ART
|
Drug: rifabutin in combination with nevirapine
IIa. arm 2a: D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks); IIb. arm 2b : D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks); |
Experimental: 3
RBT associated with LPV/r based ART
|
Drug: rifabutin in combination with lopinavir/ritonavir
IIIa. arm 3a : D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks); IIIb. arm 3b: D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks). |
Detailed Description:
Patients will be offered to participated in the study after the first 6 weeks of the nationally recommended TB treatment. All the enrolled patients will be switched to rifabutin and randomized, two weeks later, to one of the three study ARV regimens. The RBT doses will be then adapted to the allocated ARV regimen according to a cross over scheme. Three full pharmacokinetics profile will be performed at different time point : before initiation of ARV, after one month of the first RFB dosage and one month after the second RFB dosage.
![](https://webarchive.library.unt.edu/web/20130305100959im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pulmonary tuberculosis (proven by AFB positive sputum or culture)
- Having completed and adhered to 6 wks of intensive phase TB chemotherapy
- Positive HIV antibody and CD4 count >50 /mm3 and <=200
- Weight > 50 kg
- No ART in the preceding 3 months
- No more than 2 weeks or ART previously
- No grade 3 or 4 clinical or laboratory findings
- Negative pregnancy test and appropriate contraceptive measures during the duration of the trial for female of childbearing age
- Having a firm home address that is readily accessible
- Karnofsky score>=80%
Exclusion Criteria:
- History of TB within the 3 years preceding the presenting episode of TB
- Previous treatment for MDR TB
- Concomitant OI requiring additional anti-infectious treatment
- Formal contraindication to any drug used in the trial
- Diabetes mellitus requiring drug treatment
- Recreational drug or alcohol abuse
- History of drug hypersensitivity to TB or related medications
- Interrupted TB therapy for more than 1 week
- Less than 90% adherent to first 6 weeks of intensive phase chemotherapy
- Mental illness that could impair ability to give informed consent or result in poor adherence to trial protocol and therapy
- Neutropenia <1200 /L, anaemia <6.8 g/dL, liver function test > grade 2
- Requiring concomitant medications that may potentially interact with study drugs
- Pregnant or lactating women
- Karnofsky score >80%
- Any condition rendering the patient unable to understand the nature, scope, and possible consequences of thes study and to provide consent
![](https://webarchive.library.unt.edu/web/20130305100959im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
South Africa | |
Unit for Clinical and Biomedical TB Research (Medical Research Council) | |
Durban, South Africa, 4067 |
Principal Investigator: | Anthony D Harries, MD, PhD | The international Union Against Tuberculosis and Lung Diseases (IUATLD), Paris, France |
Principal Investigator: | Alexander PYM, MD | Medical Research Council, South Africa |
![](https://webarchive.library.unt.edu/web/20130305100959im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Claire Rekacewicz, French National Agency for Research on AIDS and Viral Hepatitis |
ClinicalTrials.gov Identifier: | NCT00640887 History of Changes |
Other Study ID Numbers: | ANRS12150a |
Study First Received: | February 6, 2008 |
Last Updated: | June 17, 2011 |
Health Authority: | South Africa: Medicines Control Council |
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
HIV Tuberculosis Rifabutin Pharmacokinetics South Africa |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Nevirapine Ritonavir Efavirenz Lopinavir Rifabutin Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on March 03, 2013